Eleusis, a clinical-stage life science company, terminated $446m merger agreement with Silver Spike Acquisition, a SPAC. “We are thrilled to work with the Silver Spike team, whose extensive financial and industry experience complement our expertise. We believe access to public capital markets will accelerate our efforts to transform psychedelics into modern medicines, and ultimately offers the potential to improve millions of patients’ lives while creating long-term value for our shareholders,” Shlomi Raz, Eleusis CEO and Founder. On June 9, 2022, Eleusis and Silver Spike Acquisition Corp. II agree to terminate the SPAC merge.